Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STTRIDE: Tofacitinib plus triple immunosuppressive therapy in anti-MDA5 dermatomyositis with interstitial pneumonia
jRCT2031240191Phase 2Recruiting
- Sponsor
- Chiba University Hospital
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tofacitinib in dermatomyositis (DM) and interstitial lung disease (ILD), sponsored by Chiba University Hospital. Started Jun 2024; status: recruiting.
02
Drugs
03
Conditions
dermatomyositis (DM)interstitial lung disease (ILD)
Beyond the preview
Go deeper on jRCT2031240191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240191.